Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.
Tamara Y MilderJialing LinSallie-Anne PearsonJerry R GreenfieldRichard Osborne DaySophie Lena StockerBrendon L NeuenMichael O FalsterJuliana de Oliveira CostaPublished in: British journal of clinical pharmacology (2024)
Amongst people initiating metformin from 2018 to 2020, there was an increasing proportion of SGLT2i and GLP-1 RA being used as first add-on therapy. However, the overall prevalence of add-on therapy was low. Advocacy to promote add-on therapy with cardiorenal beneficial medicines is critical to reduce type 2 diabetes morbidity and mortality.